Sapacitabine Seliciclib Dosing Regimen for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for proliferative disorders, such as cancer, often involve adverse interactions between pharmaceutical agents, leading to reduced efficacy and increased toxicity when administered together, and there is a need for a dosing regimen that maximizes the therapeutic effect while minimizing host toxicity.
Innovation Solution
A dosing regimen involving the administration of sapacitabine and seliciclib in specific cycles, where seliciclib is given 8-24 hours prior to sapacitabine, allowing for enhanced transcriptional effects on cancer cells and maximizing inhibitory effects on DNA repair pathways without adverse interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sapacitabine and seliciclib are administered together to maximize therapeutic effect, then efficacy is improved, but toxicity increases
Solution Approach 1:
Seliciclib is administered 8-24 hours before sapacitabine to pre-condition cancer cells by inhibiting CDK activity and suppressing DNA repair pathway preparation. This preliminary action makes cancer cells more susceptible to sapacitabine's cytotoxic effects while allowing the use of lower sapacitabine doses, thereby improving efficacy while reducing toxicity
Solution Approach 2:
The treatment employs periodic administration cycles where sapacitabine and seliciclib are given in specific sequences followed by rest periods. This periodic regimen allows therapeutic accumulation of effect while permitting normal tissue recovery between cycles, managing the toxicity-efficacy balance
2Reliability
If conventional cytotoxic drugs are used to treat cancer, then cell death is induced, but general host toxicity occurs
Solution Approach 1:
The combination regimen creates a localized therapeutic effect specifically in cancer cells through the sequential action of seliciclib and sapacitabine. Seliciclib preferentially affects cancer cells by inhibiting CDK complexes that are overactive in these cells, while normal cells are better protected due to their different CDK dependency patterns. This local quality differentiation allows selective cancer cell killing with reduced impact on normal tissues
Solution Approach 2:
The treatment uses a composite pharmacological approach combining two agents with different mechanisms of action: seliciclib (a CDK inhibitor that blocks cell cycle progression and suppresses DNA repair) and sapacitabine (a nucleoside analogue that induces DNA damage). This composite regimen creates synergistic anti-cancer effects while the specific dosing sequence and intervals help manage overall toxicity
Data Source
AI summary
A first aspect of the invention relates to a method of treating a proliferative disorder in a subject, said method comprising administering to the subject a therapeutically effective amount of (i) sapacitabine, or a metabolite thereof; and (ii) seliciclib; in accordance with a dosing regimen comprising at least one first treatment cycle and at least one second treatment cycle, wherein said first treatment cycle comprises: (a) administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 3 to 5 consecutive days for 2 weeks, starting on day d, where d is the first day of treatment with sapacitabine, or the metabolite thereof, in said first treatment cycle; and (b) optionally administering a therapeutically effective amount of seliciclib for 3 to 5 consecutive days for 2 weeks, starting on day (d−1) relative to the administration of sapacitabine or the metabolite thereof, in said first treatment cycle; followed by a rest period of at least 2 weeks, or until treatment-related toxicities are resolved, whichever is longer; and wherein said second treatment cycle comprises: (a) administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 3 to 5 consecutive days for 2 weeks, starting on day d, where d is the first day of treatment with sapacitabine, or the metabolite thereof, in said second treatment cycle; and (b) administering a therapeutically effective amount of seliciclib for 3 to 5 consecutive days for 2 weeks, starting on day (d−1) relative to the administration of sapacitabine or the metabolite thereof, in said second treatment cycle; followed by a rest period of at least 2 weeks, or until treatment-related toxicities are resolved, whichever is longer. Further aspects of the invention relate to a kit of parts, and corresponding uses.